Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising therapeutic target in cancer therapy. Combination chemotherapy using Tdp1 inhibitors as a component can potentially improve therapeutic response to many chemotherapeutic regimes. A new set of usnic acid derivatives with hydrazonothiazole pharmacophore moieties were synthesized and evaluated as Tdp1 inhibitors. Most of these compounds were found to be potent inhibitors with IC50 values in the low nanomolar range. The activity of the compounds was verified by binding experiments and supported by molecular modeling. The ability of the most effective inhibitors, used at non-toxic concentrations, to sensitize tumors to the anticancer drug topotecan was also demonstrated. The order of administration of the inhibitor and topotecan on their synergistic effect was studied, suggesting that prior or simultaneous introduction of the inhibitor with topotecan is the most effective.

No abstract

No abstract

No abstract

This study aims at analyzing complexation properties of two new short somatostatin analogues, their synthesis, radiolabeling with 44Sc, 207Bi, and 152Eu and stability in vitro. Short tetrapeptide Phe‐d‐Trp‐Lys‐Thr and pentapeptide Thz‐Phe‐d‐Trp‐Lys‐Thr were first conjugated with the DOTA macrocyclic chelator. These conjugates were radiolabeled with 44Sc, 207Bi, and 152Eu and characterized by thin‐layer chromatography (TLC) and HPLC. The radiochemical purity was measured using digital autoradiography and gamma spectrometry. Optimum conditions of DOTA‐conjugate labeling were found: 0.1mM, pH 8.0 to 8.4 at 90°C for DOTA‐tetrapeptide complexes with 207Bi and 152Eu; 0.05mM, pH 4.0 to 5.0 at 90°C for 44Sc‐DOTA‐tetrapeptide; 0.2mM, pH 4.0 to 5.0 at 90°C for 44Sc‐DOTA‐pentapeptide. Complexes of DOTA‐pentapeptide with 207Bi and 152Eu of radiochemical purity more than 95% were probably unstable at temperature higher than 37°C and were obtained at 37°C, pH 8.0 to 8.4 within 4 days. Mass spectra of the Eu‐DOTA‐pentapeptide revealed the presence of small fragments of the pentapeptide conjugate in the complex solution. in vitro stability studies were performed in saline in the presence of serum proteins and biologically relevant metal cations. All complexes demonstrated no cation release in vitro within 1 to 4 hours.